19/07/2021 – AB Science announces the publication of new survival data showing that masitinib extended survival in ALS by 25 months relative to placebo Download PDF Post navigationPreviousPrevious post:Validation of the Risk Management Plan by the French National Agency (ANSM) in order to restart patient enrollment in FranceNextNext post:Publication in the world-renowned journal Science confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concernRelated PostsAB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021Revenues for the first half of 2021 and update on AB Science’s activities30 September 2021
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus29 November 2021
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia22 November 2021
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS18 November 2021
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)18 October 2021
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)4 October 2021
